Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855664 | 0.99 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL6969799 | 0.96 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL18032527 | 0.93 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL31435518 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL8940284 | 0.89 | HDAC1 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL4869972 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL12815027 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL23187621 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL17825392 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 | |
| SCHEMBL5866350 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368461-B2 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| EP-1444220-B1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
| EP-1444220-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003037889-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| EP-0897913-B1 | 4-carboxamido piperidine derivatives and their use as neurokinine antagonists | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| EP-0667858-B1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LTD (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0897913-A1 | 4-carboxamido piperidine derivatives and their use as neurokinine antagonists | ZENECA LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
| US-5576333-A | ASTHMA TREATMENT | ZENECA LIMITED (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5559131-A | ANTAGONISTS OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA | ZENECA LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| US-5559132-A | ANTAGONIST OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA | ZENECA LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| EP-0667858-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010146-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | TACR1, TACR2, BDKRB1 | SMN1; SMN2 3425/4885NPC1 3642/4885RAB9A 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.